Hain Celestial to overhaul business with aim of boosting growth through fiscal 2027
Hain Celestial Group Inc. (HAIN) outlined an overhaul of its business on Wednesday that aims to boost growth and generate annualized savings of $130 million to $150 million by fiscal 2027. In a statement released ahead of an investor day, the provider of snacks and beverages said it plans to prioritize growth across five core geographies of the U.S., Canada, UK, Ireland, and Europe and give platforms of better-for-you, or BFY snacks, BFY baby & kids, BFY beverages, BFY meal prep and BFY personal care. The company expects to achieve 400 to 500 basis points of adjusted gross margin improvement and deliver $400 million in cumulative cash flow by fiscal 2027. The company's longer-term goal is for organic net sales compound annual growth rate of 3% plus, it said in a statement. The company expects to book charges of $115 million to $125 million in fiscal 2024 and fiscal 2025 to cover the costs of the restructuring. The stock has fallen 40% in the year to date, while the S&P 500 has gained 16%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-13-23 0750ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks